Brian Finrow brings the skills and experience of a lawyer to a position that, in the biotech world, is more typically occupied by a scientist. This is essential to an enterprise like Lumen, which is rethinking drug development from the ground up to emphasize speed, efficiency and ease of delivery, and whose approach is so innovative that traditional ways of thinking about IP and regulatory pathways oftentimes do not apply.
Read MoreJeffrey Goldberg is the president and CEO of Immunitas. Jeff is an experienced biotech program and brand leader with over 20 years of industry experience. He has driven programs from discovery and pre-clinical through IND, clinical trials, NDA, and commercialization in multiple therapeutic areas, including oncology, neurology, renal, and other rare and orphan diseases.
Read MoreTodd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance.
Read MoreAlison serves as the chief medical officer at Surface Oncology. She has over 20 years of experience in clinical research, oncology drug development and clinical neuro-oncology.
Read MoreNancy Lurker: President & Chief Executive Officer
Our President, CEO, and a director since September 2016, Ms Lurker has broad-ranging experience in the pharmaceutical industry.
Said Saim, PhD: Chief Technology Officer
Dr Saim has more than 25 years of product development experience.
Mike Nally is the Chief Executive Officer of Generate Biomedicines and a CEO-Partner at Flagship Pioneering. Mike brings significant experience leading global organizations and is passionate about working with teams and partners to bring innovations to patients.
Read MoreRon Cohen, M.D. is President, CEO and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for disorders of the nervous system, including multiple sclerosis, Parkinson’s disease and migraine.
Read MoreAvanish Vellanki is passionate about offering cancer patients better treatment options, and he firmly believes that precision oncology strategies are the best manner in which to achieve that goal. He has 20 years of experience across the healthcare and investment banking sectors and began his career on Wall Street at Bear, Stearns & Co. in 2004 in equity research, covering small/mid-cap biotechnology companies.
Read MoreBenjamine Liu is the co-founder and CEO of TrialSpark, a technology company that is reimagining drug development.
Read MoreAnkit Mahadevia is the CEO of Spero Therapeutics and a member of the Board of Directors. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, MA.
Read MoreJonathan Rigby is an experienced CEO with three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry. He currently serves as the CEO of Revolo Biotherapeutics, a biotechnology company setting out to revolutionize the treatment for autoimmune and allergic diseases, through the development of therapies that reset the immune system to achieve superior long-term disease remission.
Read MoreBalkrishan (Simba) Gill, Ph.D. has served as our President, Chief Executive Officer and a member of our Board of Directors since September 2015. Dr. Gill also has served on the board of directors of Realm Therapeutics PLC since 2016, and as a Venture Partner at Flagship Pioneering, a life sciences innovation enterprise, since 2015.
Read More
